Overview: Glucose Tolerance Test 3 Sample APL Panel
Introduction: The Glucose Tolerance Test 3 Sample APL Panel is a diagnostic tool designed to assess glucose tolerance using plasma samples. In India, the 3-sample OGTT (fasting, 1-hour, 2-hour after 75g glucose) is used for diagnosing diabetes/impaired glucose tolerance (~11 percent diabetes prevalence), especially in high-risk groups. High morbidity from under-testing in rural/low-SES adults, limited labs, delayed lifestyle intervention leading to progression to diabetes and complications. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for 3 glucose levels over 1-2 days with high accuracy, valuable for definitive diagnosis in prediabetes/diabetes screening. This diagnostic falls under glucose tolerance screening and targets patients with risk factors (obesity, family history), addressing accurate detection to guide diet/exercise or metformin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise glucose assessment and reducing diabetes burden. Its plasma-based approach ensures reliable measurement.
Other Names: GTT APL Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.
Historical Milestone: 3-sample OGTT standard; in India, used in diabetes programs.
Purpose: The test assesses 3 parameters including fasting glucose to guide glucose tolerance evaluation, detect diabetes/prediabetes, inform therapy.
Test Parameters: 1. Fasting Glucose, 2. 1-Hour Glucose, 3. 2-Hour Glucose.
Pretest Condition: Fasting 10-12 hours required; patients should report risk factors or symptoms.
Specimen: 3 mL plasma in NaF tube (multiple draws), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on family diabetes, obesity, symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated dysglycemia including diabetes, benefits of assessment, and minimal discomfort from multiple draws.
Procedural Considerations: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or non-compliance with load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal values diagnose diabetes/prediabetes, necessitating specialist input.
Specialist Consultation: Diabetologists should be consulted for management.
Additional Supporting Tests: HbA1c for confirmation.
Test Limitations: Requires compliance; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023.
